Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1623 1627 1628 1641 1693
This examiner grants 25% of resolved cases
Seong Jong Kim is an examiner in Tech Center 1600, assigned to Art Unit 1621. His profile is based on 4 resolved cases, which resulted in an allowance rate of 25.0 percent. This outcome provides an initial data point for applicants. The median days to allowance for these cases was 997, establishing a baseline for the timeline in his docket. Because the data set is restricted to 4 resolved cases, these figures reflect the specific history of those applications.
The interview lift for this examiner is recorded at 0.0 percent. This figure indicates that, for the 4 resolved cases on record, an interview did not change the outcome relative to the 25.0 percent allowance rate. Practitioners should consider that with 4 cases, the 0.0 percent lift does not yet reflect a long-term trend regarding the efficacy of verbal communication. As more cases are resolved in Art Unit 1621, the 997 day median pendency and the 25.0 percent allowance rate will continue to define his examination profile in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18923576 | TREATMENT OF DEPRESSION | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 18292046 | WATER SOLUBLE PRODRUG, CONJUGATES AND USES THEREOF | Non-Final OA | MERCK PATENT GMBH |
| 18846235 | ADDITIVE COMPOSITION FOR ORALLY DISINTEGRATING TABLET | Non-Final OA | Daicel Corporation |
| 18687257 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE | Non-Final OA | The Regents of the University of California |
| 18712613 | CELL-POTENT BISUBSTRATE INHIBITORS FOR NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18281528 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING THERAPY-RELATED CARDIOMYOPATHY ASSOCIATED WITH NEUTROPHIL INFILTRATION | Non-Final OA | University of Virginia Patent Foundation |
| 18596300 | METHODS OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCLUDING COMPOUNDS USEFUL THEREIN | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18594989 | Use of Cannabidiol to Improve Rehabilitation in Lung Cancer | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18706437 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION COMPRISING AT LEAST ONE MEROCYANINE AND AT LEAST ASCORBIC ACID AND/OR A DERIVATIVE THEREOF | Non-Final OA | L'OREAL |
| 18042993 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | Final Rejection | YALE UNIVERSITY |
| 18261373 | ANTIBIOTICS WITH IMPROVED DRUG RESISTANCE PROFILE | Final Rejection | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18947116 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18316755 | LYSERGIC ACID DERIVATIVES AND METHODS | Non-Final OA | The Florida State University Research Foundation, Inc. |
| 18012705 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | Non-Final OA | AstraZeneca UK Limited |
| 18705043 | ALICYCLIC ALIPHATIC 1,3-DICARBONYL DERIVATIVES USEFUL AS FRAGRANCES | Non-Final OA | GIVAUDAN SA |
| 18730668 | MOLIDUSTAT FORMULATIONS AND METHODS OF USE FOR TREATMENT OF ANEMIA IN CATS | Non-Final OA | ELANCO ANIMAL HEALTH GMBH |
| 18172771 | CHEMICAL COMPOSITIONS AND METHODS OF USE | Final Rejection | Bruker Spatial Biology, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy